Bristol Myers sees $0.35 per share charge as Mirati acquisition completes

seekingalpha01-23

Bristol Myers Squibb (NYSE:BMY) said on Tuesday that its deal to acquire the cancer drugmaker Mirati Therapeutics successfully concluded and that the transaction would negatively impact its 2024 adj. ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment